|
Registered number:
FOR THE PERIOD ENDED 31 DECEMBER 2025
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
COMPANY INFORMATION
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
CONTENTS
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
STRATEGIC REPORT
FOR THE PERIOD ENDED 31 DECEMBER 2025
The directors present the Strategic Report of Catalent Nottingham Limited (the "company") for the period ended 31 December 2025.
These accounts are for the 18 month period from 1 July 2024 to 31 December 2025. The comparatives represent the year ended 30 June 2024.
Catalent Inc, the ultimate parent, was acquired by Novo Holdings A/S in an all-cash transaction on 18 December 2024. Due to the acquisition, the company has moved its reporting period from a 30 June close to a 31 December close so as to align with the ultimate parent's reporting periods. There have been no changes impacting the running of the business since the transaction closed.
Subsequent to the 31 December 2025 period end, Catalent entered into a Stock Sale Agreement for the sale of the company to US-based entity Codis. The proposed transaction was publicly announced on 6 July 2026 and is expected to complete on 31 July 2026, subject to the satisfaction of the remaining closing conditions. Based on the information currently available, the directors do not expect the proposed transaction to have a material impact on the company's principal activities or its future development as described in the Strategic Report. Revenue for the 18 month period ended 31 December 2025 was £16.3m (year ended 2024: £14.5m), primarily due to a change in focus for the company over the last 18 months, targeting our offering more towards the early phase development of products with the aim of feeding the lifecycle of these molecules into the wider Catalent group.
Within our revenue generating business model, we are focused on:
∙Pharmaceutical Development Services - Focused on the early phases of development of small molecule compounds, including, "challenging" compounds that are considered difficult to formulate;
∙Clinical Trial Manufacturing Services - Customised manufacturing and packaging, primarily for phase 1 and 2 clinical trials, including the manufacturing of tablets, capsules, topicals, dry powder inhaled products and liquids; and
∙Advanced Analytical Consulting Services - Data driven decision support and regulatory support services across preclinical and clinical development programs.
During the period, we continued to enhance our expertise and offering in pharmaceutical development services, clinical trial manufacturing and advanced analytical consulting services.
The company continues to play a key role within the wider group, adding value through developing molecules that go on to be commercialised in other sites across the Catalent network. Management remains focused on leveraging the company's strengths to further support group-wide objectives.
Page 1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
STRATEGIC REPORT (CONTINUED)
FOR THE PERIOD ENDED 31 DECEMBER 2025
The directors rely on certain key performance indicators to measure and manage the business. The key performance indicators that the directors find relevant is turnover generation, EBITDA contribution, net assets and average employee headcount in comparison to prior years and budget targets.
In the 18 month period, turnover was £16.3m (year ended 30 June 2024: £14.5m). In the 18 month period, EBITDA was £254k (year ended 30 June 2024: £2,288k). EBITDA is defined as profit/loss before tax, excluding interest, depreciation, amortisation, tax, amounts deemed exceptional by management and management recharges. The company has net assets of £4.0m (30 June 2024: £8.7m) at the period end. In the 18 month period, headcount has decreased to 163 (year ended 30 June 2024: 185). Management continues to review all areas of headcount and make strategic decisions based on capacity, demand and other ongoing factors that impact the business. Revenue has a direct correlation to EBITDA. The company has implemented a number of cost savings initiatives throughout the period to help mitigate the impact that any reduction in revenue has on EBITDA. The primary cost for the company remains the staff costs which are constantly monitored against the sales demand to ensure that margins are maintained. The company further implemented strategies throughout the period to help transition the change in focus. The outlook for Financial Year 2026 remains positive on the back of these strategies, however, the company's leadership team are actively reviewing the cost base of the company for opportunities should a risk to growth materialise.
Page 2
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
STRATEGIC REPORT (CONTINUED)
FOR THE PERIOD ENDED 31 DECEMBER 2025
Management have identified below a summary of the main risks that could potentially impact the business operating and financial performance.
Economic Risks
Through the normal course of its activities, the company has exposure to foreign exchange fluctuations due to the global nature of the revenues. The company is exposed to USD and Euro denominated revenues. Company spend in foreign currencies is limited and therefore the company has no currency hedges or financial instruments in place at company level to protect against exchange rate variations. The company reduces the risk by billing customers in company currency where possible and holding balances in different currencies to manage payments and receipts more effectively.
The macroeconomic outlook has become more uncertain as the impact of higher inflation on the cost of living has increased. The company continues to monitor and mitigate inflation risk within the UK and surrounding global markets. Management mitigates inflation risk via having a strong procurement team in place, internal cost savings initiatives and strategic budgeting. Management have considered the risk from the conflict in the Middle East and US Tariffs and have deemed it minimal based on the low impact on trading since these events have occurred.
Liquidity and Cash-flow Risk
The company faces liquidity and cash flow risks from customers and suppliers. The cash-flow risk is actively managed on a regular basis, through regular cashflow forecasting processes. The company can call upon the Catalent cash pooling facility at any given moment via an email and subsequent cash transfer once approved by treasury.
Legislative/regulatory risks
Currently the company is regulated by the MHRA (Medicines & Healthcare products Regulatory Agency) in the UK, the main national regulatory body.
Regulatory changes may give rise to risks related to the company's ability to service these markets, either impacting its capabilities or impacting the company indirectly through changes to customers' products requirements. The company is upgrading its capabilities and systems continuously to ensure it meets all current reasonably foreseen regulatory changes.
Credit risk
The principal credit risk arises from the company's trade debtors. In order to manage this risk, management reviews and approves the credit terms of all new clients. Further, a regular review of the credit position of existing clients is also performed.
All potential areas of financial risk are regularly monitored and reviewed by the directors and local management. Preventative or corrective measures are taken as necessary.
This report was approved by the board and signed on its behalf.
Page 3
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
DIRECTORS' REPORT
FOR THE PERIOD ENDED 31 DECEMBER 2025
The directors present their report and the financial statements for the period ended 31 December 2025.
These accounts are for the 18 month period from 1 July 2024 to 31 December 2025. The comparatives represent the year ended 30 June 2024.
The loss for the period, after taxation, amounted to £4,687,921 (year ended 30 June 2024: loss £2,256,800).
The directors who served during the period, and up to the date of signing this report, were:
Page 4
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
CATALENT NOTTINGHAM LIMITED
DIRECTORS' REPORT (CONTINUED)
FOR THE PERIOD ENDED 31 DECEMBER 2025
The financial statements have been prepared on a going concern basis.
In assessing the appropriateness of the going concern basis of preparation, the directors have considered the company's cash flow forecasts for a period of at least twelve months from the date of approval of these financial statements.
On 6 July 2026, Codis announced its intention to acquire 100% of the share capital of the company. Completion of the proposed acquisition remains subject to certain closing conditions and, accordingly, there can be no certainty as to whether, or when, the transaction will complete.
Should the proposed acquisition not proceed, the company will remain under the ownership of its existing ultimate parent company, Catalent, Inc. Catalent, Inc. has confirmed its intention to continue providing financial support to the company for a period of at least twelve months from the date of approval of these financial statements, as evidenced by a letter of financial support provided to the directors.
Should the proposed acquisition complete, the company would cease to be part of the Catalent group and would therefore no longer be able to rely on the financial support currently available from Catalent, Inc. At the date of approval of these financial statements, the company's post-acquisition funding arrangements are not yet fully within the company's control and remain dependent upon completion of the transaction and implementation of replacement funding arrangements.
In assessing the company's ability to continue as a going concern, the directors have considered both the scenario in which the proposed acquisition completes and the scenario in which it does not complete. Having considered the company's forecasts and the funding support expected to be available under each scenario, the directors have concluded that it is appropriate to prepare the financial statements on a going concern basis.
However, the outcome and timing of the proposed acquisition of 100% of the company's share capital by Codis, together with the dependency on replacement funding arrangements should the transaction complete, represent a material uncertainty that may cast significant doubt on the company's ability to continue as a going concern.
The financial statements do not include any adjustments that would arise if the company were unable to continue as a going concern.
Page 5
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
CATALENT NOTTINGHAM LIMITED
DIRECTORS' REPORT (CONTINUED)
FOR THE PERIOD ENDED 31 DECEMBER 2025
Subsequent to the period end, Catalent entered into a Stock Sale Agreement for the sale of the company to US-based entity Codis. The proposed transaction was publicly announced on 6 July 2026 and is expected to complete on 31 July 2026, subject to the satisfaction of the remaining closing conditions.
Based on the information currently available, the directors do not expect the proposed transaction to have a material impact on the company's principal activities or its future development as described in the Strategic Report.
The auditor, Grant Thornton UK LLP, will be proposed for reappointment in accordance with section 485 of the Companies Act 2006.
This report was approved by the board and signed on its behalf.
Page 6
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF CATALENT NOTTINGHAM LIMITED
We draw attention to note 2.4 in the financial statements, which indicates that on 6 July 2026, Codis announced its intention to acquire 100% of the share capital of Catalent Nottingham Limited. Completion of the proposed acquisition remains subject to a number of conditions and there can be no certainty as to whether, or when, the transaction will complete. Completion of the transaction would also result in the company leaving the Catalent group and the financial support currently available from Catalent Inc. would no longer be available. As stated in note 2.4, these events or conditions, along with the other matters as set forth in note 2.4, indicate that a material uncertainty exists that may cast significant doubt on the company's ability to continue as a going concern. Our opinion is not modified in respect of this matter.
In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.
Page 7
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF CATALENT NOTTINGHAM LIMITED (CONTINUED)
We are responsible for concluding on the appropriateness of the directors’ use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify the auditor’s opinion. Our conclusions are based on the audit evidence obtained up to the date of our report. However, future events or conditions may cause the company to cease to continue as a going concern.
Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.
In our opinion, based on the work undertaken in the course of the audit:
∙the information given in the Strategic Report and the Director's Report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
∙the Strategic Report and the Director's Report have been prepared in accordance with applicable legal requirements.
Page 8
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF CATALENT NOTTINGHAM LIMITED (CONTINUED)
Matters on which we are required to report by exception
Page 9
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF CATALENT NOTTINGHAM LIMITED (CONTINUED)
Page 10
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
INDEPENDENT AUDITOR'S REPORT TO THE MEMBERS OF CATALENT NOTTINGHAM LIMITED (CONTINUED)
Use of our report
This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an Auditor's Report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.
Senior Statutory Auditor
for and on behalf of
Statutory Auditor, Chartered Accountants
Page 11
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
STATEMENT OF COMPREHENSIVE INCOME
FOR THE PERIOD ENDED 31 DECEMBER 2025
Page 12
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
STATEMENT OF FINANCIAL POSITION
AS AT 31 DECEMBER 2025
Page 13
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
STATEMENT OF FINANCIAL POSITION (CONTINUED)
AS AT 31 DECEMBER 2025
The financial statements were approved and authorised for issue by the
The notes on pages 16 to 35 form part of these financial statements.
Page 14
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
STATEMENT OF CHANGES IN EQUITY
FOR THE PERIOD ENDED 31 DECEMBER 2025
Page 15
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2025
Catalent Nottingham Limited is a private company limited by shares, incorporated in England and Wales. Its registered number is 03397582, and its registered head office is located at 8 Orchard Place, Nottingham Business Park, Nottingham, Nottinghamshire, NG8 6PX.
2.Accounting policies
The preparation of financial statements in compliance with FRS 101 requires the use of certain critical accounting estimates. It also requires management to exercise judgement in applying the company's accounting policies (see note 3).
The following principal accounting policies have been applied:
The company has taken advantage of the following disclosure exemptions under FRS 101:
∙the requirements of IFRS 7 Financial Instruments: Disclosures;
∙the requirements of the second sentence of paragraph 110 and paragraphs 113(a), 114, 115, 118, 119(a) to (c), 120 to 127 and 129 of IFRS 15 Revenue from Contracts with Customers;
∙the requirement in paragraph 38 of IAS 1 'Presentation of Financial Statements' to present comparative information in respect of:
- paragraph 79(a)(iv) of IAS 1;
- paragraph 73(e) of IAS 16 Property, Plant and Equipment; and
- paragraph 118(e) of IAS 38 Intangible Assets;
∙the requirements of paragraphs 10(d), 10(f), 16, 38A, 38B, 38C, 38D, 40A, 40B, 40C, 40D, 111 and 134-136 of IAS 1 Presentation of Financial Statements;
∙the requirements of IAS 7 Statement of Cash Flows;
∙the requirements of paragraph 17 and 18A of IAS 24 Related Party Disclosures;
∙the requirements of paragraphs 130(f)(ii), 130(f)(iii), 134(d)-134(f) and 135(c)-135(e) of IAS 36 Impairment of Assets; and
∙the requirements of paragraph 88C and 88D of IAS 12 Income Taxes.
-results.
Page 16
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2025
2.Accounting policies (continued)
The financial statements have been prepared on a going concern basis.
In assessing the appropriateness of the going concern basis of preparation, the directors have considered the company's cash flow forecasts for a period of at least twelve months from the date of approval of these financial statements.
On 6 July 2026, Codis announced its intention to acquire 100% of the share capital of the company. Completion of the proposed acquisition remains subject to certain closing conditions and, accordingly, there can be no certainty as to whether, or when, the transaction will complete.
Should the proposed acquisition not proceed, the company will remain under the ownership of its existing ultimate parent company, Catalent, Inc. Catalent, Inc. has confirmed its intention to continue providing financial support to the company for a period of at least twelve months from the date of approval of these financial statements, as evidenced by a letter of financial support provided to the directors.
Should the proposed acquisition complete, the company would cease to be part of the Catalent group and would therefore no longer be able to rely on the financial support currently available from Catalent, Inc. At the date of approval of these financial statements, the company's post-acquisition funding arrangements are not yet fully within the company's control and remain dependent upon completion of the transaction and implementation of replacement funding arrangements
In assessing the company's ability to continue as a going concern, the directors have considered both the scenario in which the proposed acquisition completes and the scenario in which it does not complete. Having considered the company's forecasts and the funding support expected to be available under each scenario, the directors have concluded that it is appropriate to prepare the financial statements on a going concern basis.
However, the outcome and timing of the proposed acquisition of 100% of the company's share capital by Codis, together with the dependency on replacement funding arrangements should the transaction complete, represent a material uncertainty that may cast significant doubt on the company's ability to continue as a going concern.
The financial statements do not include any adjustments that would arise if the company were unable to continue as a going concern.
Functional and presentation currency
Transactions and balances
Page 17
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2025
2.Accounting policies (continued)
Development services contracts generally take the form of short-term, fee-for-service arrangements. Performance obligations vary, but frequently include biologic cell-line development, formulation, analytical stability testing, and other services related to product development. Each promised service is typically assessed as a distinct performance obligation. The transaction price is generally fixed and based on amounts specified in the contract for each promised service. Revenue is recognised over time as performance obligations are satisfied, as the company's performance does not create an asset with an alternative use and the company has an enforceable right to payment for performance completed to date. Progress towards satisfaction of performance obligations is measured using an output method, based on the achievement of contractually defined milestones or deliverables. Revenue is recognised when the relevant milestone or deliverable is achieved, as this best reflects the transfer of control of services to the customer. Billing can vary by contract, but typically include invoicing upon achievement of milestones or, in some cases, in advance of performance.
Page 18
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2025
2.Accounting policies (continued)
If it is not possible to distinguish between the research phase and the development phase of an internal project, the expenditure is treated as if it were all incurred in the research phase only.
Page 19
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2025
2.Accounting policies (continued)
The estimated useful lives range as follows:
Page 20
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2025
2.Accounting policies (continued)
Depreciation is provided on the following basis:
Assets under construction are not depreciated until the assets are available for use. They are then transferred to the relevant tangible fixed asset category and depreciated in line with the depreciation policy.
The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.
Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.
Page 21
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2025
2.Accounting policies (continued)
Page 22
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2025
Estimates and underlying assumptions are reviewed on an ongoing basis. Estimates are based on historical experience and other assumptions that are considered reasonable in the circumstances. The actual amount or values may vary in certain instances from the assumptions and estimates made. Changes will be recorded, with corresponding effect in the financial statements, when, and if, better information is obtained. Critical judgements and sources of estimation uncertainty that management have made in the process of applying accounting policies disclosed herein and that have a significant effect on the amounts recognised in the financial statements relate to the following: Estimates Alternative Performance Measures "APMs" (see Strategic Report) The directors exercise judgement in determining adjustments to apply to FRS 101 measurements in order to derive suitable APMs which are used by management to provide additional information on the trends and performance of the group. The directors believe that EBITDA is a key APM. This measure is used for performance analysis by the board, is not defined by FRS 101 and not intended to be a substitute from FRS 101 measurements. They may not be directly comparable with other companies' APMs. Judgements Indicators of Impairment Management applies judgment to evaluate whether internal or external triggers exist that suggest an asset may be impaired. These considerations include significant changes in the technological, market, economic, or legal environment in which the company operates, as well as internal metrics such as physical obsolescence, under performance against budget, or planned restructures. Going concern In assessing the going concern assumption, the Directors have exercised significant judgment regarding the availability of future funding. The company is reliant on the continued financial support of its parent company, Catalent Inc. The parent company has provided a formal, legally binding commitment to provide unconditional financial support to the company for a period of at least 12 months from the date of approval of these financial statements. This support ensures that the company can meet its liabilities as they fall due and continue its operations without material disruption.
Page 23
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2025
Analysis of turnover by country of destination:
Page 24
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2025
Page 25
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2025
Page 26
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2025
Page 27
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2025
12.Taxation (continued)
Deferred tax balances have been measured at 25%, being the enacted UK corporation tax rate applicable to future periods at the Statement of Financial Position date.
Page 28
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2025
Page 29
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2025
Page 30
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2025
Page 31
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2025
Page 32
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2025
The company's capital and reserves are as follows:
Share premium account
Capital redemption reserve
Retained earnings
Page 33
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2025
The company operates a defined contributions pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. The pension cost charge represents contributions payable by the company to the fund and amounted to £
Based on the information currently available, the directors do not expect the proposed transaction to have a material impact on the company's principal activities or its future development as described in the Strategic Report. The company’s ultimate controlling party is
Page 34
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
NOTES TO THE FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 31 DECEMBER 2025
The impact of the restatement on the comparative Statement of Comprehensive Income was as follows: This restatement relates solely to the presentation of expenses within the Statement of Comprehensive Income and has no impact on total net assets or profit for the financial year.
Page 35
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||